San Francisco, 14 April 2030: The Report U.S. Blood Collection Market Size, Share & Trends Analysis Report By Site (Venous, Capillary), By Application (Diagnostics, Treatment), By End Use, By Age, By Demography, And Segment Forecasts, 2025 - 2030
The U.S. blood collection market size is expected to reach USD 2.08 billion by 2030, according to a new study by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.91% from 2030 to 2030. The increasing prevalence of chronic and infectious diseases, growing number of blood transfusions, and rising prevalence of hematological disorders are primarily driving the overall market growth. As per CDC data, approximately 38 million adults were suffering from diabetes in 2022. In addition, obesity is linked to up to 53% of new type 2 diabetes cases annually. Thus, the increasing prevalence of diabetes is expected to boost the demand for vacutainers in recurring diagnostic tests, such as blood sugar assays.
The growing prevalence of hematological disorders highlights the need for vacutainers to diagnose these disorders, driving the demand for vacuum blood collection devices. For instance, the Leukemia & Lymphoma Society reports that approximately one person is diagnosed with blood cancer every 3 minutes. This increasing burden of hematological disorders necessitates effective blood collection methods for diagnosis and monitoring, thereby propelling the blood collection market.
The growing advancements in technology have made the blood collection market more sophisticated and accurate. Moreover, expansion of Point-of-Care Testing (POCT) solutions in various healthcare settings, including pharmacies, urgent care centers, and clinics, can drive the demand for blood collection in the U.S. Community pharmacies are increasingly playing a pivotal role in collection services, leveraging their accessibility and patient trust to enhance healthcare delivery. Thus, community pharmacies are expanding their role in POCT, offering convenient and accessible diagnostic services, including blood collection, directly to patients in the U.S.
The growing demand for blood collection products is driven by the increasing volume of diagnostic procedures requiring blood samples, including disease screenings and medication monitoring. Regular tests are essential for evaluating and managing chronic conditions such as diabetes, cardiovascular disease, and cancer. Medical professionals favor these tests for their efficiency, ease of use, and reliability in ensuring accurate sample collection and preservation.
Request sample report of U.S. Blood Collection Market@ https://www.grandviewresearch.com/industry-analysis/us-blood-collection-market-report/request/rs1
Moreover, the rising prevalence of chronic and infectious diseases is a key factor driving demand for blood collection devices. As the U.S. becomes increasingly globalized, health risks extend beyond borders, with economic integration, industrialization, urbanization, and large-scale migration all contributing to various public health challenges. In addition, the growing incidence of chronic conditions like diabetes and cardiovascular diseases is projected to increase the need for collection devices, as these illnesses require frequent testing and monitoring. Reliable blood collection methods are essential for effective management of such conditions. According to CDC data, around 38 million adults in the U.S. were living with diabetes in 2022 and the obesity cases are projected to grow up to 53% of new type 2 diabetes cases each year. Consequently, the increasing prevalence of diabetes is expected to drive demand for vacutainers used in routine diagnostic tests, including sugar assays.
Furthermore, the increasing demand for blood transfusions is a significant driver of the market growth. According to the National Blood Collection and Utilization Survey (NBCUS), there was a 1.7% rise in collected Red Blood Cell (RBC) units between 2025 and 2021. In 2021, 11.78 million RBC units were collected, while 10.76 million units were transfused. In addition, the collection of whole blood units for allogeneic, non-directed donations grew by 0.7%, reaching 9.84 million units, and apheresis RBC collections increased by 7.3% to 1.93 million units. Blood or platelets are needed every two seconds in the U.S., underscoring the steady demand for these components. Each day, approximately 29,000 units of RBCs, nearly 5,000 units of platelets, and 6,500 units of plasma are required. In total, nearly 16 million blood components are transfused annually in the U.S.
The increasing incidence of hematological disorders is a major driver for the use of blood collection devices. Conditions such as anemia, sickle cell disease, bleeding disorders like hemophilia, and clotting issues, as well as cancers including myeloma, lymphoma, and leukemia, are all on the rise. In the U.S., blood cancer claims a life every nine minutes, amounting to approximately 157 deaths daily or over six deaths every hour. In 2023 alone, leukemia, lymphoma, and myeloma are projected to cause around 57,380 deaths in the U.S., representing 9.4% of all cancer-related deaths.
An estimated 437,337 individuals in the U.S. are either living with or in remission from leukemia, while around 879,242 people are in the same condition with lymphoma. Blood clots affect approximately 900,000 Americans each year, leading to about 100,000 deaths annually. Notably, fewer than one in four people show any noticeable signs or symptoms of a blood clot, underscoring the silent but significant impact of this cond
